Bayer's radium-223 CRPC drug gets priority review
This article was originally published in Scrip
Executive Summary
The US FDA has granted a priority review to Bayer HealthCare’s new drug application (NDA) for Radium Ra 223 dichloride (radium-223) as a treatment for patients with castration-resistant prostate cancer (CRPC) whose disease has spread to the bone.